Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality